TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04755387
Drug: Ticagrelor 60/45mg
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-hospital treatment with standard strategy ticagrelor 90mg twice daily, following de-escalation strategy ticagrelor 60/45mg twice daily after discharge for 12 months.
Study: NCT04899414
Drug: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexamethasone 40mg intravenously daily on day 1-4; azacytidine 100mg intravenously daily on day 1-5; Pegaspargase 3750 IU intravenously daily on day 1； Tislelizumab 200 mg IV on Day 1 of each 21-day as a cycle.
Study: NCT05531942
Drug: Ginkgo Diterpene Lactone Meglumine Injection
Normalized name: citronellene lactone
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.
Study: NCT06498531
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 1x125mg acetazolamide in the morning, 1x125mg in the evening, starting 24 hours before departure to 3600 m.
Study: NCT04402073
Drug: Sonidegib
Normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sonidegib is a selective smoothened inhibitor that inhibits the sonic hedgehog-signaling pathway. It is used in patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Study: NCT04402073
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours. The application route is through the veins.
Study: NCT04402073
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine is a nitrosourea used in the treatment of brain tumours and Hodgkin's disease. The application route is oral.
Study: NCT04402073
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine sulfate (VCR) is an inhibitor of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vincristine sulfate is indicated in acute leukemia, Hodgkin's disease, non-Hodgkin's lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. The application route is through the vein.
Study: NCT05323734
Drug: Ganaxalone
Normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GNX will be administered
Study: NCT06302621
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each study treatment cycle lasts 21 days: Afatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
Study: NCT06302621
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each study treatment cycle lasts 21 days: Pemigatinib, oral, once daily, per protocol determined number of days per cycle and per protocol determined dosage
Study: NCT05593770
Drug: Fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.
Study: NCT06540209
Drug: Bacillus clausii
Normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will be give Bacillus clausii for 5 days
Study: NCT05289908
Drug: Pemetrexed (1)
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....
Study: NCT05289908
Drug: Pemetrexed (2)
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.
Study: NCT05289908
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.
Study: NCT05289908
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
Study: NCT06296706
Drug: Docetaxel for injection (Albumin-bound)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks
Study: NCT06296706
Drug: Taxotere (docetaxel)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere, by intravenous infusion, every 3 weeks.
Study: NCT06540209
Drug: ORS
Normalized name: HORSE
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS will be given to all children for 5 days
Study: NCT06641453
Drug: Fludarabine Phosphate for Injection
Normalized name: Fludarabine Phosphate for Injection
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously at a dose of 20-30 mg/m²/day on days -5, -4, and -3.
Study: NCT06641453
Drug: Cyclophosphamide for Injection
Normalized name: Cyclophosphamide for Injection
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously at a dose of 300-500 mg/m²/day on days -5, -4, and -3.
Study: NCT06171802
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg empagliflozin daily for six months
Study: NCT04858997
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib,125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study: NCT04858997
Drug: AI
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AI, orally once daily (continuously)
Study: NCT06475820
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age \> 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day.
Study: NCT05024214
Drug: Lenvatinib + Envafolimab
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.
Study: NCT05024214
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
Study: NCT06407232
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 480 mg taken orally once daily, for 84 days
Study: NCT05634460
Drug: potassium hydroxide
Normalized name: Potassium Hydroxide
DrugBank: Potassium hydroxide (DB11153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC.
Study: NCT06446648
Drug: ICG
Normalized name: ICG136
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
Study: NCT05003700
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg once daily (QD) oral dosing.
Study: NCT05003700
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg intravenously every 3 weeks.
Study: NCT05145816
Drug: Belantamab mafodotin 2.5 mg/kg (8 weeks)
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2.5 mg/kg IV Belantamab mafodotin IV every 8 weeks for Part 1
Study: NCT05145816
Drug: Belantamab mafodotin 1.9 mg/kg (8 weeks)
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.9 mg/kg IV Belantamab mafodotin IV every 8weeks for Part 1
Study: NCT05145816
Drug: Belantamab mafodotin 1.4 mg/kg (12 weeks)
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.4 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Study: NCT05145816
Drug: Belantamab mafodotin 1.9 mg/kg (12 weeks)
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.9 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Study: NCT05145816
Drug: Belantamab mafodotin every 4 weeks, 6 weeks,8 weeks, or 12 weeks as determined by Part 1 recommended dosages
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belantamab mafodotin Dose 1.0 mg/kg, 1.4 mg/kg, 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks, 8 weeks or 12 weeks as determined by Part 1 recommended dosages.
Study: NCT05145816
Drug: Belantamab mafodotin 1.0 mg/kg (12 weeks)
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.0 mg/kg Belantamab mafodotin IV every 12 weeks for Part 1
Study: NCT06673238
Drug: ABBV-722
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT06672133
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given：IV
Study: NCT06520553
Drug: BI 1569912 (C-14)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: unlabelled BI 1569912 mixed with \[14C\]- labelled BI 1569912
Study: NCT06520553
Drug: BI 1569912 (C-13)
Normalized name: Urea C 13
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: \[13C\]- labelled BI 1569912
Study: NCT06689241
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg
Study: NCT06689241
Drug: rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg
Study: NCT06686108
Drug: Azacitidine (AZA) Days 1 - 5
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine, ih, 32mg/m2/d, days 1-5 of each 28-day cycle
Study: NCT06686108
Drug: Decitabine (DAC)
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: decitabine, 5mg/m2/d, days 1-5 of each 28-day cycle.
Study: NCT06686108
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: venetoclax, 400mg/d, days 1-7 of each 28-day cycle
Study: NCT06686914
Drug: Cannabidiol (CBD) Oil 300mg
Normalized name: CANNABIDIOL OIL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) Oil 300mg, 1 dose
Study: NCT06686914
Drug: Cannabidiol (CBD) Oil 150mg
Normalized name: CANNABIDIOL OIL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) Oil 150mg, 1 dose
Study: NCT05691361
Drug: ADX-324
Normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: siRNA duplex oligonucleotide
Study: NCT05347641
Drug: Penpulimab
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5
Study: NCT06209372
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
DrugBank: Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (DB10799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol infusion
Study: NCT04775979
Drug: diphenylcyclopropenone (DPCP)
Normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depigmenting agent
Study: NCT06519994
Drug: Artesunate vaginal inserts
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will self-administer 200 mg of Artesunate vaginal insert daily for 5 days, on weeks 1, 3, 5.
Study: NCT05157997
Drug: Casirivimab and Imdevimab Antibody Cocktail
DrugBank: Imdevimab (DB15940)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The study will utilize REGEN-COV 8,000mg (4,000 mg of each monoclonal antibody) given as IV infusion on day of transplant and 2400mg (1,200 mg of each monoclonal antibody) on post-operative day 1.
Study: NCT06124924
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a starting dose of a SGLT2i will be prescribed for the participant for pickup at discharge via the UMMC discharge pharmacy. The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills, but this can be adjusted to other SGLT2i or other doses in the outpatient setting by either Dr. Murphy or by the participants' established providers, typically based on insurance company preferences among the three FDA-approved SGLT2i.
Study: NCT05892042
Drug: Rivaroxaban 15 MG [Xarelto]
Normalized name: rivaroxaban 15 MG [Xarelto]
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eligible subjects randomized into experimental group will receive rivaroxaban 15mg daily in addition to dual anti platelet therapy unless confirmed resolution of the left ventricular thrombus.
Study: NCT04565301
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: adductor canal block
Study: NCT04565301
Drug: neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adductor canal block
Study: NCT06543069
Drug: Sintilimab, Bevacizumab , Pemetrexed , Cisplatin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
Study: NCT00000690
Drug: Dextran sulfate
Normalized name: dextran sulfate
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06312787
Drug: VX-118
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets and Suspension for Oral Administration
Study: NCT04959331
Drug: Fosfomycin Trometamol Salt
Normalized name: trometamol
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin 3 g 2 sachets, taken orally, once daily for two days
Study: NCT04959331
Drug: Nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin 50 mg pills, taken orally, two pills/8 hours, for five days
Study: NCT04959331
Drug: Pivmecillinam
Normalized name: pivmecillinam
DrugBank: Pivmecillinam (DB01605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 400 mg pills. taken orally, one pill/8 hours, for three days
Study: NCT04959331
Drug: Fosfomycin Trometamol Salt
Normalized name: trometamol
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin 3 g one sachet, taken orally, for one day
Study: NCT06075277
Drug: BI 1810631
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1810631
Study: NCT05101551
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib will be administered in escalating doses based on current dose level.~* Dose Level 1: 400 µg/m2/dose once daily~* Dose Level 2: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 3: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 4: 600 µg/m2/dose BID on Day 1, then daily on Days 2 to 5~* Dose Level 5: 600 ug/m2/dose BID on Day 1, then daily on Days 2 to 5 and 15 to19
Study: NCT05101551
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV route on Days 1 to 5~* Dose Level -2: 1 mg/m2/dose once daily by IV days 1 to 5~* Dose Level -1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 1: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 2: 2 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 3: 3 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 4: 4 mg/m2/dose once daily by IV days 1 to 5~* Dose Level 5: 4 mg/m2/dose once daily by IV days 1 to 5
Study: NCT05101551
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose (IV) of gemcitabine on Day 1 of each 28 day cycle for 1 cycle.~* Dose Level -2: 600 mg/m2/dose once daily by IV days 1~* Dose Level -1: 600 mg/m2/dose once daily by IV days 1~* Dose Level 1: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 2: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 3: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 4: 1200 mg/m2/dose once daily by IV days 1~* Dose Level 5: 1200 mg/m2/dose once daily by IV days 1
Study: NCT04784143
Drug: Midomafetamine
Normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg midomafetamine HCl followed by a supplemental dose of 60 mg
Study: NCT04802590
Drug: Ibrutinib 560 mg
Normalized name: ibrutinib 560 MG
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 560mg/d continuously from C1D2 to end C24
Study: NCT04802590
Drug: Venetoclax 10 MG Oral Tablet [Venclexta]
Normalized name: venetoclax 10 MG Oral Tablet [Venclexta]
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20mg/d from C2D1 to C2D7
Study: NCT04802590
Drug: Venetoclax 50 MG Oral Tablet [Venclexta]
Normalized name: venetoclax 50 MG Oral Tablet [Venclexta]
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50mg/d from C2D8 to C2D14
Study: NCT04802590
Drug: Venetoclax 100 MG Oral Tablet [Venclexta]
Normalized name: venetoclax 100 MG Oral Tablet [Venclexta]
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
Study: NCT05494619
Drug: Crovalimab
Normalized name: Crovalimab
DrugBank: Crovalimab (DB16128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight ≥ 40 kilograms (kg) and \<100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Day 1, followed by crovalimab 340 mg SC injections on Days 2, 8, 15 and 22 in all participants.
Study: NCT06342609
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg per day of Colchicine orally administered
Study: NCT04810676
Drug: CKD-383
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05303857
Drug: Semaglutide Pen Injector
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection of the semaglutide once weekly
Study: NCT06527131
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medical antibiotics
Study: NCT05163028
Drug: HBI-2376
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP2 Inhibitor
Study: NCT00549289
Drug: cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05645887
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.
Study: NCT05568147
Drug: Aspirin tablet
Normalized name: Aspirin Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When patients are randomized into the intervention group, they will receive aspirin at the dosage of 100mg orally once every day.
Study: NCT05077709
Drug: IO102-IO103 in combination with pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The experimental drug IO102-IO103 is for SC injection and consist of IDO and PD-L1 peptides
Study: NCT05696678
Drug: Intrathecal Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive a spinal anesthesia with a dose of 10.5 mg of bupivacaine 0.75% (1.4 ml),10 mcg of fentanyl (0.2 ml) and 100 mcg of morphine (0.2 ml) for cesarean delivery. At the end of surgery, at wound closure, a 19 Gauge 150 mm catheter will be placed under the fascia and will be linked to an elastometric pump filled with sterile saline (600 ml). A bolus of 20 ml will be administered, and an 8 ml/h infusion will be started. The catheter will be removed at 72 hours.